These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 20554645)

  • 1. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
    Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
    Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
    Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
    Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.
    Chen J; Li D; Schaefer RF; Mehta JL
    J Cardiovasc Pharmacol; 2004 Oct; 44(4):446-52. PubMed ID: 15454852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
    Chen J; Li D; Schaefer R; Mehta JL
    Atherosclerosis; 2006 Feb; 184(2):295-301. PubMed ID: 16005008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
    Krämer S; Kron S; Wang-Rosenke Y; Loof T; Khadzhynov D; Morgera S; Kawachi H; Shimizu F; Martini S; Neumayer HH; Peters H
    Am J Physiol Renal Physiol; 2008 Apr; 294(4):F801-11. PubMed ID: 18216152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
    Lassila M; Seah KK; Allen TJ; Thallas V; Thomas MC; Candido R; Burns WC; Forbes JM; Calkin AC; Cooper ME; Jandeleit-Dahm KA
    J Am Soc Nephrol; 2004 Aug; 15(8):2125-38. PubMed ID: 15284298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
    Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y
    Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
    Engelhorn T; Doerfler A; Heusch G; Schulz R
    Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
    Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
    Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
    Park JK; Mervaala EM; Muller DN; Menne J; Fiebeler A; Luft FC; Haller H
    J Hypertens; 2009 Mar; 27(3):599-605. PubMed ID: 19262227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
    Hofni A; El-Moselhy MA; Taye A; Khalifa MM
    Eur J Pharmacol; 2014 Dec; 744():173-82. PubMed ID: 25446917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat.
    Bishnoi HK; Mahadevan N; Balakumar P
    Pharmacol Res; 2012 Oct; 66(4):349-56. PubMed ID: 22796657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease--a dose-response relationship study.
    Saha SA; LaSalle BK; Clifton GD; Short RA; Tuttle KR
    Am J Ther; 2010; 17(6):553-8. PubMed ID: 19829095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of statins on diabetic nephropathy in db/db mice.
    Tamura Y; Murayama T; Minami M; Yokode M; Arai H
    Int J Mol Med; 2011 Nov; 28(5):683-7. PubMed ID: 21833465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
    Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
    J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin-induced arrest in progression of renal disease.
    Vidt DG; Cressman MD; Harris S; Pears JS; Hutchinson HG
    Cardiology; 2004; 102(1):52-60. PubMed ID: 15073451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease.
    Abe M; Maruyama N; Yoshida Y; Ito M; Okada K; Soma M
    Endocr J; 2011; 58(8):663-74. PubMed ID: 21670545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.